9 Meters Biopharma, Inc. (NMTRQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick Answer9 Meters Biopharma, Inc. (NMTRQ) trades at $0.0001. 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare digestive diseases and gastrointestinal disorders. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for NMTRQ: NMTRQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
9 Meters Biopharma, Inc. (NMTRQ) Healthcare & Pipeline Overview
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical firm specializing in innovative therapies for rare digestive diseases, with a focus on unmet medical needs in gastrointestinal disorders, particularly through its lead candidate, Vurolenatide.
What Is the Investment Thesis for NMTRQ?
9 Meters Biopharma, Inc. operates in a niche segment of the biotechnology industry focused on rare digestive diseases, which presents unique growth opportunities. The company's lead candidate, Vurolenatide, is in Phase 3 trials, potentially positioning it for market entry should it receive regulatory approval. The market for treatments addressing short bowel syndrome and related gastrointestinal disorders is significant, with increasing awareness and demand for effective therapies. However, the company faces substantial risks, including its recent bankruptcy filing, which complicates its operational viability and future funding prospects. The outcome of ongoing clinical trials and the ability to secure partnerships or funding will be critical in determining the company’s future trajectory.
Based on FMP financials and quantitative analysis
NMTRQ Key Highlights
Market Cap: $0.00B due to bankruptcy proceedings.
- ROE: -375.6%, indicating significant financial distress.
- Free Cash Flow: -$0.02B, reflecting ongoing operational challenges.
- Beta: 9.33, suggesting high volatility in stock performance.
- Dividend Yield: None, as the company does not currently distribute dividends.
Who Are NMTRQ's Competitors?
NMTRQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ALBO Albireo Pharma, Inc. | $44.15 | 0.00% | $916M | — |
| RLYB Rallybio Corporation | $16.65 | +0.06% | $88.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $10.24 | -0.10% | $93.6M | 78 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.08 | -1.21% | $170M | 75 5-pillar |
| NAGE Niagen Bioscience Inc | $2.44 | +0.41% | $190M | 70 5-pillar |
| QTTB Q32 Bio Inc. | $8.45 | -2.31% | $252M | 67 5-pillar |
| CLYM Climb Bio, Inc. | $8.81 | -13.54% | $506M | 67 5-pillar |
| ZVRA Zevra Therapeutics, Inc. | $9.53 | -2.85% | $566M | 91 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NMTRQ's Key Strengths?
Innovative pipeline with multiple drug candidates targeting rare diseases.
- Strong focus on unmet medical needs in gastrointestinal health.
- Established partnerships with other biopharmaceutical firms.
What Are NMTRQ's Weaknesses?
Recent bankruptcy filing raises concerns about financial stability.
- Limited operational scale with only 10 employees.
- High volatility in stock performance due to market conditions.
What Are the Key Risks for NMTRQ?
Financial instability due to the recent bankruptcy filing, impacting operations and funding.
- Regulatory hurdles that could delay or prevent approval of drug candidates.
- High competition in the biotechnology sector, which may hinder market penetration.
What Threats Does NMTRQ Face?
- Intense competition from other biotechnology firms.
- Regulatory challenges in drug approval processes.
- Market volatility impacting investor confidence and funding availability.
What Are NMTRQ's Competitive Advantages?
- Specialization in rare diseases provides a unique market position with less competition.
- Strong pipeline of innovative therapies targeting unmet medical needs.
- Established partnerships with reputable organizations enhance credibility and research capabilities.
- Intellectual property protections for proprietary drug candidates create barriers to entry.
- Clinical-stage advancements in drug development increase potential for future revenue streams.
What Does NMTRQ Do?
Founded with the mission to address significant gaps in treatment for rare digestive diseases, 9 Meters Biopharma, Inc. has positioned itself as a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from gastrointestinal disorders. Headquartered in Raleigh, North Carolina, the company has focused its efforts on creating effective treatments for conditions that currently lack adequate therapeutic options. Its primary product candidate, Vurolenatide, is a long-acting injectable glucagon-like peptide-1 that has advanced to Phase 3 clinical trials for the management of short bowel syndrome, a debilitating condition that significantly impacts patients' quality of life. In addition to Vurolenatide, 9 Meters Biopharma has developed a diverse pipeline of products, including NM-136, a humanized monoclonal antibody targeting obesity and related conditions; NM-102, a small molecule peptide designed to prevent antigen entry into systemic circulation; and NM-003, a proprietary glucagon-like peptide-2 receptor agonist aimed at preventing acute graft versus host disease. The company has also partnered on Larazotide, an 8-amino acid peptide that is currently in Phase 2 clinical trials for multi-system inflammatory syndrome. Despite its innovative pipeline and strategic licensing agreements with entities such as Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS, 9 Meters Biopharma faced significant financial challenges, leading to a voluntary petition for liquidation under Chapter 7 of the U.S. Bankruptcy Code on July 17, 2023.
What Products and Services Does NMTRQ Offer?
- Develop therapies for rare digestive diseases and gastrointestinal disorders.
- Focus on innovative treatments for conditions with unmet medical needs.
- Conduct clinical trials to evaluate the efficacy and safety of its drug candidates.
- Engage in partnerships and licensing agreements to enhance its research capabilities.
- Target specific conditions such as short bowel syndrome, obesity, and acute graft versus host disease.
- Utilize advanced biopharmaceutical technologies to create long-acting injectable therapies.
How Does NMTRQ Make Money?
- Generate revenue through the development and commercialization of pharmaceutical products.
- Engage in licensing agreements with other biopharmaceutical companies to expand product offerings.
- Conduct clinical trials funded by partnerships and grants to support research and development.
- Focus on niche markets with high unmet medical needs to capture market share.
- Leverage intellectual property and proprietary technologies to create competitive advantages.
What Industry Does NMTRQ Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development. With a growing focus on personalized medicine and targeted therapies, companies like 9 Meters Biopharma are positioned within a market that is expected to expand significantly. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, driven by advancements in drug development and increasing prevalence of chronic diseases. However, the competitive landscape is intense, with numerous players vying for market share in therapeutic areas that address unmet medical needs.
Who Are NMTRQ's Key Customers?
- Patients suffering from rare digestive diseases and gastrointestinal disorders.
- Healthcare providers seeking effective treatment options for their patients.
- Pharmaceutical partners interested in licensing or collaborating on drug development.
- Investors and stakeholders looking for innovative biopharmaceutical opportunities.
- Regulatory bodies involved in the approval and oversight of new therapies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
9 Meters Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Raleigh, US. The company is led by CEO Peter H. R. Green. NMTRQ has traded publicly since 2016.
Earnings Track Record
9 Meters Biopharma, Inc. has beaten Wall Street's EPS estimate in 2 of its last 4 reported quarters — more hits than misses. Reported results have landed about 17.4% below estimates on average.
NMTRQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
NMTRQ Latest News
No recent news available for NMTRQ.
NMTRQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NMTRQ.
Price Targets
Wall Street price target analysis for NMTRQ.
NMTRQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NMTRQ; grades run from A+ (80-100) to F (below 30).
Leadership: Peter H. R. Green
CEO
Peter H. R. Green has a robust background in the biopharmaceutical industry, bringing extensive experience in managing clinical-stage companies. He has held various leadership roles throughout his career, focusing on drug development and strategic partnerships. His educational background includes advanced degrees in life sciences, equipping him with the knowledge necessary to lead a biopharmaceutical firm effectively.
Track Record: Under Peter H. R. Green's leadership, 9 Meters Biopharma has developed a promising pipeline of therapeutic candidates, advancing Vurolenatide to Phase 3 clinical trials. His strategic vision has fostered partnerships that enhance the company's research capabilities, although recent financial challenges have significantly impacted the company's trajectory.
NMTRQ OTC Market Information
The OTC Other tier includes companies that do not meet the financial standards required for listing on major exchanges like NYSE or NASDAQ. This tier often features smaller companies or those undergoing financial difficulties, which can lead to less visibility and liquidity in the market.
- OTC Tier: OTC Other
- Potential for high volatility due to low trading volumes.
- Limited financial disclosures may obscure the company's true financial health.
- Increased risk of fraud or mismanagement in less regulated environments.
- Verify the company's financial statements and disclosures.
- Assess the management team's experience and track record.
- Evaluate the company's pipeline and clinical trial progress.
- Investigate any pending litigation or regulatory issues.
- Review market conditions and competitive landscape.
- Partnerships with established biopharmaceutical firms.
- Presence of a qualified management team with relevant experience.
- History of clinical trial advancements and regulatory submissions.
NMTRQ Healthcare Stock FAQ
What are the main risks for NMTRQ?
The main risks for 9 Meters Biopharma, Inc. include ongoing financial instability due to its recent bankruptcy filing, which raises concerns about its operational viability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Company is undergoing bankruptcy proceedings, which may affect the accuracy and completeness of information.